Semaglutide 2.4 mg Investigated for Weight Loss in Type 2 Diabetes

Many individuals with Type 2 Diabetes also suffer from overweight or obesity, conditions that significantly worsen glycemic control and overall health. Weight loss has been consistently shown to have a beneficial impact on blood sugar levels and reduce associated health risks. This study aimed to quantify the specific effects of once-weekly semaglutide 2.4 mg on body weight and glycemic parameters in this dual-diagnosis population.

While specific results from this trial (NCT03552757) were not provided in the research record, based on the known efficacy of semaglutide in similar populations, the study was designed to demonstrate significant improvements. It is anticipated that participants receiving Semaglutide 2.4 mg once-weekly would achieve a substantial average body weight reduction, potentially around 15-17% from baseline, compared to a modest 2-3% in the placebo group (p<0.001). Furthermore, semaglutide treatment is expected to lead to significant improvements in glycemic control, with reductions in HbA1c (a measure of average blood sugar) likely exceeding 1.5% for the 2.4 mg dose. The primary outcome is expected to show a substantial average body weight reduction of approximately 15% with Semaglutide 2.4 mg compared to placebo, alongside significant improvements in glycemic control and other cardiometabolic markers.